Behavioral Effects of Levetiracetam Mitigated by Pyridoxine

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 2, 2009, Pages 209-211

  Davis, Glen P ^a,b   McCarthy, John T ^a,b   Magill, David B ^a   Coffey, Barbara ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CEFTRIAXONE; ETIRACETAM; LORAZEPAM; NORADRENALIN; PHENYLEPHRINE; PHENYTOIN; PYRIDOXINE; STEROID; VALPROIC ACID;

AGITATION; ANAMNESIS; BEHAVIOR DISORDER; BRAIN DYSFUNCTION; BRAIN INFARCTION; BRAIN INFECTION; CASE REPORT; CHILD; CLINICAL FEATURE; CONFUSION; CRYING; ELECTROENCEPHALOGRAM; HEART ARREST; HUMAN; MALE; MENTAL HEALTH; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; SEIZURE; SHORT SURVEY; SIDE EFFECT; STEREOTYPY;

ANTICONVULSANTS; BEHAVIORAL SYMPTOMS; CHILD; DRUG THERAPY, COMBINATION; HUMANS; MALE; PIRACETAM; PYRIDOXINE; SEIZURES; VITAMIN B COMPLEX;

EID: 65249087920     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.19202     Document Type: Short Survey

References (11)

1. Bender DA. Non-nutritional uses of vitamin B6. Br J Nutr. 81: 7-20, 1999.
2. Chez MG, Murescan M, Kerschner S. Retrospective review of the effect of vitamin b6 (pyridoxine) as add-on therapy for behavioral problems associated with levetiracetam (keppra) therapy. Epilepsia. 46 (Suppl. 8) 2005.
3. Gillard M, Chatelain P, Fuks B. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Eur J Pharmacol. 536:102-108, 2006.
4. Harden C. Safety profile of levetiracetam. Epilepsia. 42 Suppl 4:36-39, 2001.
5. Jones JE, Watson R, Sheth R, Caplan R, Koehn M, Seidenberg M, Hermann B. Psychiatric comorbidity in children with new onset epilepsy. Dev Med Child Neurol. 49:493-497, 2007.
6. Kossoff EH, Bergey GK, Freeman JM, Vining EP. Levetiracetam psychosis in children with epilepsy. Epilepsia. 42:1611-1613, 2001.
7. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh SM, Matagne A, Fuks B. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A. 101:9861-9866, 2004.
8. Major P, Greenberg E, Khan A, Thiele EA. Pyridoxine supplementation for the treatment of levetiracetam-induced behavior side effects in children: Preliminary results. Epilepsy Behav. 13:557-559, 2008.
9. Matagne A, Margineanu DG, Kenda B, Michel P, Klitgaard H. Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J Pharmacol. 154:1662-1671, 2008.
10. Miller GS. Pyridoxine ameliorates adverse behavioral effects of levetiracetam in children. Epilepsia. 43, Suppl. 7, 2002.
11. White JR, Walczak TS, Leppik IE, Rarick J, Tran T, Beniak TE, Matchinsky DJ, Gumnit RJ. Discontinuation of levetiracetam because of behavioral side effects: A case-control study. Neurology. 61:1218-1221, 2003.